Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer A single-institutional ...

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

At Huntsman Cancer Institute, you receive comprehensive, multidisciplinary care for soft-tissue sarcomas. Our Sarcoma Care Team provides personalized and compassionate care at every step, from ...

Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

Soft tissue sarcoma is a type of cancerous tumor that forms in the body’s soft tissues, such as muscle, fat, fibrous tissue, and blood vessels. If it occurs in the shoulder, it might feel like a ...

Soft tissue sarcomas are a rare group of cancers that develop in soft tissue. They can develop almost anywhere in your body, including in your hip, thigh, and groin. Soft tissue sarcomas are rare ...

Sarcoma is a type of cancer that originates in the bones or soft tissue. Soft tissue sarcoma (STS) most often begins in the arms and legs but can also occur in other body parts. Soft tissues include ...

Canine soft tissue sarcomas (STS) constitute a heterogeneous group of mesenchymal tumours that present diverse morphological and clinical profiles. These neoplasms commonly affect the skin and ...

Causes of Soft Tissue Sarcoma:The exact soft tissue sarcoma causes remain unclear, but several risk factors have been identified. These include a family history of inherited conditions such as ...

A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses against aggressive soft tissue sarcomas, based on early phase II data ...